Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NA |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | RT-qPCR, Western blot, RIP, Luciferase reporter assay |
| Sample | NSCLC tissues,lung epithelium cell (BEAS-2B) and NSCLC cells (H446, A549) |
| Expression Pattern | up-regulated |
| Function Description | NORAD was up-regulated in DDP-resistant NSCLC tissues and cells. NSCLC patients with high NORAD expression suffered a poor prognosis. NORAD knockdown resensitized H446/DDP and A549/DDP to DDP. Besides, NORAD acted as a molecular sponge of miR-129-1-3p. MiR-129-1-3p showed a low level of expression in DDP-resistant NSCLC tissues. |
| Pubmed ID | 31894841 |
| Year | 2020 |
| Title | NORAD Accelerates Chemo-Resistance of Non-Small-Cell Lung Cancer via Targeting at miR-129-1-3p/SOX4 Axis |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |